Medicine and Dentistry
Combination Therapy
100%
Endocrine Disease
100%
Somatostatin Derivative
100%
Acromegaly
83%
Insulin-Like Growth Factor 1
66%
Pegvisomant
33%
Growth Hormone Secreting Adenoma
33%
Hyperprolactinemia
33%
Pasireotide
33%
Diagnosis
16%
Diabetes Mellitus
16%
Polyclonal Antibody
16%
Monotherapy
16%
Prolactin
16%
Receptor Antagonist
16%
Octreotide
16%
Dopamine 2 Receptor Stimulating Agent
16%
Pituitary Adenoma
16%
Angiopeptin
16%
Transsphenoidal Surgery
16%
Pharmacology, Toxicology and Pharmaceutical Science
Combination Therapy
100%
Endocrine Disease
100%
Somatostatin Derivative
100%
Acromegaly
83%
Insulin-Like Growth Factor 1
66%
Hyperprolactinemia
33%
Growth Hormone Secreting Adenoma
33%
Pegvisomant
33%
Pasireotide
33%
Diabetes Mellitus
16%
Receptor Antagonist
16%
Remission
16%
Prolactin
16%
Monotherapy
16%
Octreotide
16%
Angiopeptin
16%
Polyclonal Antibody
16%
Dopamine 2 Receptor Stimulating Agent
16%
Hypophysis Adenoma
16%
Neuroscience
Somatostatin Derivative
100%
Endocrine Disease
100%
Acromegaly
83%
Insulin-Like Growth Factor 1
66%
Pegvisomant
33%
Pasireotide
33%
Receptor Antagonist
16%
Agonist
16%
Diabetes Mellitus
16%
Polyclonal Antibody
16%
Octreotide
16%
Lanreotide
16%
Prolactin
16%
Pituitary Adenoma
16%